Q32 Bio Inc (QTTB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $248.07M
Last updated: Nov 17, 2026 at 4:15 PM ET
Q32 Bio Inc (QTTB) Statistics
Q32 Bio (QTTB) has a market cap of $248.07M. Its share count is up 177.95% from a year earlier. It holds $289.59M more cash than debt, 116.74% of its market cap.
Total Valuation
| Market Cap | $248.07M |
|---|---|
| Latest price (Nov 17, 2026) | $8.63 |
Key Dates
The next earnings report is expected on May 3, 2027, covering the quarter ending Mar 31, 2027.
| Next Earnings Date | May 3, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 5.5x and 1.0x.
| P/E Ratio | 2.6x |
|---|---|
| P/S Ratio | 5.5x |
| Forward P/S | 744.2x |
| P/B Ratio | 1.0x |
Price Statistics
The stock is up 299.54% over 52 weeks and trades 4.96% below its 50-day average.
| Beta (1Y) | 0.07 |
|---|---|
| 52-Week Change | +299.54% |
| 1-Month Change | +10.78% |
| 3-Month Change | -45.52% |
| 6-Month Change | +42.17% |
| 5-Year Change | -91.35% |
| Total Return (1Y) | +299.54% |
| Total Return (3Y CAGR) | -5.05% |
| Total Return (5Y CAGR) | -38.08% |
| Return vs SPY (1Y) | +266.95% |
| Max Drawdown (1Y) | -64.83% |
| Max Drawdown (3Y) | -97.31% |
| Sharpe Ratio (1Y) | 0.96 |
| Correlation with SPY (1Y) | 0.01 |
| 50-Day Average | $9.08 |
| 200-Day Average | $9.53 |
| 52-Week Range | $1.91 to $23.57 |
| RSI (14 Days) | 45.0 |
| Average Volume (20 Days) | 366.09K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 56.34x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 56.34x |
|---|---|
| Quick Ratio | 56.34x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is 11.21% and return on assets is 10.85% over the last 12 months.
| Return on Equity (ROE) | 11.21% |
|---|---|
| Return on Assets (ROA) | 10.85% |
| Return on Capital Employed (ROCE) | 11.09% |
| ROA (5Y Average) | -33.01% |
| ROIC (5Y Average) | -55.81% |
| Asset Turnover | 0.30x |
Scores
QTTB has an Altman Z-Score of 19.09, in the safe zone above 2.99, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 19.09 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $53.74M over the last 12 months.
| Revenue | $53.74M |
|---|---|
| Gross Profit | $53.74M |
| Operating Income | $18.38M |
| Pretax Income | $32.25M |
| Net Income | $32.25M |
| EBITDA | $32.75M |
| EBIT | $32.40M |
| Reported EPS (TTM) | $3.34 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 96.79% of the $297.20M in total assets.
| Cash and Equivalents | $289.59M |
|---|---|
| Total Debt | $0 |
| Net Cash | $289.59M |
| Net Cash Per Share | $8.51 |
| Working Capital | $285.96M |
| Shareholder Equity | $287.67M |
| Book Value Per Share | $8.46 |
| Total Assets | $297.20M |
| Total Liabilities | $9.53M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$20.02M |
|---|---|
| FCF Per Share | -$0.67 |
| Depreciation and Amortization | $486.00K |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 34.20%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | 34.20% |
| Pretax Margin | 60.02% |
| Net Margin | 60.02% |
| EBITDA Margin | 60.95% |
| EBIT Margin | 60.29% |
Growth
Revenue grew 155.87% a year over 3 years.
| Revenue Growth (3Y CAGR) | +155.87% |
|---|---|
| Revenue Growth (5Y CAGR) | +81.85% |
Dividends and Yields
QTTB does not pay a dividend.
| Earnings Yield | 38.46% |
|---|---|
| Buyback Yield | -85.56% |
| Shareholder Yield | -85.56% |
Stock Splits
The last split was a 1-for-18 reverse split on Mar 26, 2024.
| Last Split Date | Mar 26, 2024 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:18 |
Analyst Forecast
Consensus estimates put revenue growth at -87.55% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -87.55% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About QTTB
What is QTTB's market cap?
Q32 Bio has a market cap of $248.07M.
What is QTTB's P/E ratio?
Q32 Bio has a trailing P/E ratio of 2.6x.
How many shares of QTTB are outstanding?
Q32 Bio has 34.02M shares outstanding. The count is up 177.95% from a year earlier.
Does QTTB pay a dividend?
No. Q32 Bio does not pay a dividend.
How much debt does QTTB have?
Q32 Bio has $0 of total debt and $289.59M of cash and equivalents, a net cash position of $289.59M.
QTTB pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors